RWM
BMRN icon

Rialto Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Rialto Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.21K Buy
56
+38
+211% +$2.08K ﹤0.01% 931
2026
Q1 		$1.02K Buy
18
+5
+38% +$292 ﹤0.01% 1100
2025
Q4 		$773 Buy
13
+2
+18% +$109 ﹤0.01% 1086
2025
Q3 		$596 Buy
11
+4
+57% +$229 ﹤0.01% 1131
2025
Q2 		$385 Buy
+7
New +$412 ﹤0.01% 1233

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Rialto Wealth Management's BMRN Position: Q2 2026 in Review

Rialto Wealth Management increased its BioMarin Pharmaceuticals (BMRN) stake by 211% in Q2 2026, buying an estimated $2.08K and bringing the position to 56 shares worth $3.21K. The position accounts for ﹤0.01% of the portfolio, ranked #931.

Rialto Wealth Management first reported a position in BMRN in Q2 2025 and has held it in 5 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Rialto Wealth Management held 56 shares of BioMarin Pharmaceuticals worth $3.21K as of Q2 2026.
  • Rialto Wealth Management bought 38 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $2.08K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #931 holding.
  • Rialto Wealth Management first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.